CD274 and neoplasm: It aimed to explore their efficacy in patients irrespective of their PD-L1 tumor status and design involved two sub-studies: Sub-study A focused on patients with PD-L1+ tumors (≥25% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) and evaluated the safety and clinical activity of durvalumab compared to standard of care (SoC) options such as erlotinib, gemcitabine, or vinorelbine.